Crystal structures of resorcin[4]arene and pyrogallol[4]arene complexes with DL-pipecolinic acid. Model compounds for the recognition of the pipecolinyl ring, a key fragment of FK506, through C–H⋯π interaction

•Host–guest complexation of aromatic cyclic tetramers (RCT or PCT) with pipecolinic acid (pipeH) in crystal and in solution.•Piperidine ring of pipeH incorporated into the cavity of RCT or PCT through C–H⋯π interactions with π-rings of RCT or PCT.•Ligand-mediated capsule-like dimeric structures, [(RCT or PCT)·L-pipeH·D-pipeH·(RCT or PCT)], are formed.•A model for the recognition of the pipecolinyl ring of FK506 by its binding protein through C–H⋯π interaction is provided.•C–H⋯π interaction as a strategy for the structure-based drug design is suggested.

Resorcin[4]arene (resorcinol cyclic tetramer, abbreviated as RCT) or pyrogallol[4]arene (pyrogallol cyclic tetramer, PCT) form host–guest 1:1 complexes with DL-pipecolinic acid (DL-pipeH), RCT·DL-pipeH·EtOH·8H2O (1), PCT DL-pipeH·EtOH·4H2O (2), and PCT·DL-pipeH·3H2O (3), whose crystal structures have been determined. In each complex, the pipeH ligand is incorporated into the bowl-shaped cavity of the RCT or PCT host molecules through C–H⋯π interactions between alkyl protons of the piperidine ring of pipeH and π-rings of RCT or PCT, forming an [(RCT/PCT)·pipeH] structural fragment. In 1 and 3, two [(RCT/PCT) pipeH] fragments self-associate across an inversion center to form a guest-mediated, obliquely declined dimeric structure [(RCT/PCT)·L-pipeH·D-pipeH (RCT/PCT)]. In 2, each PCT-capped pipeH ligand bridges to two adjacent PCT molecules to form guest-mediated, optically-discrete helical polymers [PCT·L-pipeH]n or [PCT·D-pipeH]n. An 1H NMR experiment shows that the complexation through C–H⋯π interaction between the piperidine ring of pipeH and π-rings of RCT or PCT occurs also in solution, with the binding constants of 9.7 ± 0.6 M−1 for RCT and 26.5 ± 1.5 M−1 for PCT. These complexes provide a synthetic model for the recognition of the pipecolinyl-ring moiety, a key constituent of immunosuppressant drugs such as FK506, FK520 or rapamycin, by their binding proteins through C–H⋯π interaction.

Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide